Biocells

Established in 2009 and based in Beijing, China, Biocells is an innovative drug discovery and development company for neurological diseases, focusing on the prevention and treatment of neurological damage in the full disease cycle of stroke, among others. The company has been recognized as a national high-tech enterprise, and has obtained 36 domestic and international invention patents for its neurocellular protective agent products (including 11 patents in the countries where Europe is in force). In November 2023, it closed a round of series B+ funding. By building a platform for small molecule and peptide drug research and development, in vitro molecular and cellular level drug screening, and in vivo animal level drug efficacy evaluation, the company provides services such as prevention and treatment of neurological injuries throughout the disease cycle of stroke, neuroprotection of ischemic and hemorrhagic strokes, cerebral edema, and neuro prosthetics.

Specific drugs include BXOS110, a neuro cellular protective agent, and BXOS116 and BXOS401, which are used for nerve repair and nerve regeneration during the recovery period of stroke. The company's net profit for 2022 is CNY -30. 8 million, and for Jan-Jul in 2023 is CNY -17. 69 million.

The company will use the series B+ funding raised in November 2023 to advance BXOS110, a Class 1 innovative drug for the treatment of ischemic stroke, to clinical phase II, and to file INDs for BXOS116 and BXOS401, two Class 1 innovative drug products for neural repair and neural regeneration in the recovery phase of stroke.